{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-089815","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.000052+00:00","generated_at":"2026-06-11T19:29:10.696808+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Structure Therapeutics reports Q2 net loss $23.3M; completes Phase 2a enrollment for GSBR-1290","bullets":["Net loss of $23.3M for Q2 2023 vs $15.5M for Q2 2022; includes $1.7M stock-based compensation.","Cash, equivalents and short-term investments of $224.6M at June 30, 2023; expected to fund operations through at least 2025.","R&D expenses $19.4M for Q2 2023 vs $10.2M in Q2 2022, driven by GLP-1R franchise advancement.","Completed enrollment in 12-week Phase 2a study of oral GLP-1 agonist GSBR-1290 (94 participants); topline data expected latter half Q4 2023.","Appointed Ted W. Love, M.D. to Board of Directors; preparations underway for global Phase 2b study in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-089815","json":"https://secwatch.observer/filing/0001104659-23-089815.json","markdown":"https://secwatch.observer/filing/0001104659-23-089815.md","text":"https://secwatch.observer/filing/0001104659-23-089815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/0001104659-23-089815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/tm2323266d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:29:10.696808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22cc582d829ef4cd6cbf3eca5ce84bf0eabcfecf","claim":"Structure Therapeutics Inc. reported the second quarter ended June 30, 2023 results: net income Net loss totaled $23.3 million.","evidence_excerpt":"Structure Therapeutics Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the second quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1888886/000110465923089815/0001104659-23-089815-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss totaled $23.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}